TCT-603 Proximal Coronary Artery Stenting: DES Versus BMS and LAD Versus the Rest  by Calais, Fredrik et al.
TCT-600
Angiographic and clinical outcomes of paclitaxel coated balloon angioplasty
versus uncoated balloon angioplasty in Drug Eluting Stent Restenosis: Insights
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Background: In PEPCAD-DES late loss as well as the need for repeat revascularization
was significantly reduced with drug coated balloon (DCB) angioplasty compared with
plain old balloon angioplasty (POBA) for drug-eluting stent (DES) restenosis (clinical
trials.gov NCT00998439). We now evaluated whether the use of DCB is different in
paclitaxel DES restenosis or non-paclitaxel DES restenosis.
Methods: 110 patients with a DES restenosis of either Sirolimus- (SES), Everolimus-
(EES) or Paclitaxel-eluting (PES) stents in a native coronary artery with indication for
percutaneous coronary intervention with a reference diameter ranging from 2.5mm to 3.5
mm and lesion length less or equal to 22 mm were randomized to treatment with either
DCB or POBA in six centers. 38 patients were randomized to POBA and 72 patients to
DCB. Patients suffered from repeat restenotic lesion (2nd) in 55.6% (N50) in DCB
group and 52.6% (N20) in POBA population. In the DCB group restenosis was located
in SES (N41, 56.9%), PES (N20, 27.7%) or EES (N11, 15.3%). Numbers for
POBA group were SES (N27, 71.1%), PES (N7, 18.4%) or EES (N3, 13.2%).
Results: DCB as compared with POBA significantly reduced late loss in PES restenosis
and non-PES restenosis with 0.460.50mm vs. 1.581.03mm (p0.002) and
0.310.54mm vs. 0.900.67mm (p0.001), respectively. Furthermore, TLR rates were
lower with DCB versus POBA for PES restenosis (5% vs. 57.1%, p0.001) and non-PES
restenosis (18.5% vs. 32.3%, p0.002). Late loss did not differ for PES versus SES
lesions with DCB treatment (0.46 vs. 0.31mm, p0.123). DCB was superior to POBA for
treatment of a first restenosis and forsecond restenosis with a late loss of 0.350.60mm
vs. 0.650.60mm (p0.128) and 0.490.61mm vs. 1.340.76mm (p0.001), respec-
tively.
Conclusions: Paclitaxel coated balloon angioplasty was superior to POBA for treatment
of PES and non-PES restenosis. DCB effect on late loss did not differ between type of
DES.
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Background: Drug-eluting stents constitute a major achievement in preventing resteno-
sis, concerns remain regarding the increased inflammatory and thrombogenic responses
associated with the polymers used. This analysis focuses on outcomes in patients
receiving the polymer-free microporous rapamycin-eluting stent system YUKON-Choice
(Yukon-DES, Translumina, Hechingen, Germany).
Methods: From 01/2006-09/2008 all consecutive patients (pts) receiving Yukon-DES
(2,5mm diameter) were prospectively enrolled in our registry. 6-months angiographic
and long-term clinical outcomes were analysed. The primary endpoint was cumulative
long-term major adverse cardiac events (MACE).
Results: 701 pts with 724 lesions (1050 stents) were included in our registry. Mean age
was 65.710 years (73% male). Risk factors included hypercholesterolemia (57.6%),
hypertension (74.8%), and diabetes (35.5%); table 1. Indication for percutaneous coronary
intervention was acute coronary syndrome in 32.2%. 76% of the lesions were of Type
B2/C, target vessel was left anterior descending artery in 35.2%, and 23.2% were chronic
total occlusions. Lesion length was 24.65.2 mm and mean stent diameter was 2.80.4
mm; table 1. A total of 511 pts (72%) underwent 6-months angiographic follow-up, binary
restenosis was noted in 23.5%. At 5 years clinical outcomes of 625/701 (89%) followed
patients were: cardiac death 5.8%; myocardial infarction 3.4%; and target vessel
revascularisation 24.6%. The cumulative five-year incidence of MACE was 35.4% (6.7%
per year). Incidence of stent thrombosis (ST) was 2.86% (30/1050) [definite 0.86%;
probable 0.29%; possible 1.8%]. Incidence of very late (1 year) definite/possible ST was
0.29%)].
Baseline characteristics
Age (years) 65.7 10
Male 512 (73.0%)
History of PCI 372/701 (53.1%)
History of CABG 130/701 (18.5%)
History of MI 401/701 (57.2%)
Clinical presentation
Acute coronary syndrome 226/701 (32.2%)
Stable angina/silent ischemia 475/701 (67.8%)
Current smoker 149/701 (21.3%)
Hypertension 524/701 (74.8%)
Diabetes 249/701 (35.5%)
Insulin treated 89/701 (12.7%)
Hypercholesterolemia 404/701 (57.6%)
Renal insufficiency 67/701 (9.6%)
Left ventricular ejection fraction
Mean 54.813.7%
Range 9-88%
Angiographic characteristics
Lesion length 24 mm 171 (23.6%)
ACC/AHA lesion type B2/C 555 (76.6%)
Lesion in bypass graft 72 (9.9%)
Pre-index procedure ISR 109 (15.1%)
Total occlusion 168 (23.2%)
Left main artery lesion 11 (1.5%)
Left anterior descending artery lesion 255 (35.2%)
Right coronary artery lesion 231 (31.9%)
Left circumflex lesion 227 (31.2%)
Bifurcation lesion 53 (7.3%)
Multiple study stents 253 (34.9%)
Predilatation performed 277 (26.4%)
Postdilatation performed 105 (10%)
Maximum postdilatation pressure (atm)
Mean 15.3 5.1
Range 8 – 25
Maximum stent deployment pressure
(atm)
Mean 15.6 1.7
Range 8 – 24
Mean stent diameter (mm) 2.8 0,4 mm
Total study stent length (mm) 24.6 5.2
Conclusions: Our registry data suggests that the implantation of YUKON-DES is feasible
and safe, but binary restenosis and target vessel revascularisation were frequently observed.
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Background: Proximal coronary artery disease is associated with a poorer prognosis
compared to disease in the distal coronary arteries. PCI of a culprit lesion in the left
anterior descending artery (LAD) may have a worse prognosis than PCI of the proximal
left circumflex (LCX) or right coronary arteries (RCA). The possible disparity in risk may
be attenuated by stenting strategy. The aim of the present study was to evaluate outcome
after PCI of solitary proximal stenoses of the LAD as compared to the LCX and the RCA.
Methods: We used data from the Swedish angiography and angioplasty registry
(SCAAR), a national registry including all patients undergoing percutaneous coronary
intervention (PCI) in Sweden. From 2005 to 2011 all cases of proximal one- vessel
disease, treated with PCI, were identified. The patients were stratified according to culprit
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vessel and to stent type (bare metal stent (BMS) or drug-eluting stent (DES)). The results
were adjusted for background, and procedural factors. The primary outcome variables
were mortality, restenosis and stent thrombosis (ST).
Results: 7840 patients treated for a single proximal stenosis were identified. DES was used
in 35.5% of patients. The use of DES as compared to BMS in the proximal LAD was
associated with a lower restenosis rate (HR 0.39 CI 0.27- 0.55), a lower mortality (HR 0.58 CI
0.41-0.82) and a non-significant reduction in ST (HR 0.48 CI 0.12-1.91) However, in the
proximal RCA and LCX, DES was not associated with a lower restenosis rate (HR 0.86 CI
0.50-1.48, HR 0.55 CI 0.19-1.61, respectively), or mortality (HR 1.48 CI 0.92-2.40, HR 0.80
CI 0.39-1.63, respectively). There was no difference in ST rate in the RCA (HR 1.24 CI
0.65-2.39). In the LCX there were too few ST events to allow meaningful evaluation.
Conclusions: In this study of 6 years of stent implantations indexed in a national PCI registry
with complete coverage and follow-up DES compared to BMS in the proximal LAD was
associated with a lower incidence of restenosis and mortality without added risk of stent
thrombosis. In contrast DES in proximal LCX and RCA was not associated with lower event
rates. Our retrospective data support a particular indication for DES in the proximal LAD.
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Background: The SYNTAX Score (SS) is a useful angiographic tool to manage patients
with multivessel coronary artery disease (CAD) requiring coronary revascularization.
Discrepancy in SS between cath-lab personnel has been published. However, the score
variability and impact in every type of lesion has not reported. Our purpose was to assess
interobserver variability and impact in SS within lesion characteristics.
Methods: We selected coronary angiograms with left main and/or three-vessel CAD
disease without previous revascularization. After completing the basic training available
at the official SS website, two interventional cardiologists (IC) calculated global (n98
patients, 413 lesions) as well as per lesion SS (in 209/413 lesions, 50.6%). We analysed
global variability (Kappa and Bland Altman), per-lesion inter-observer variability (per-
centage of agreement and Kappa) and impact (percentage of total error observed and
multivariable model if discrepancy between observers was  3 points per lesion).
Results: Global SS interobserver variability was acceptable: Kappa 0,70 (0,59 – 0,81).
Visual analysis through Bland Altman was good, without systematic errors. Mild
disagreement in the total lesions per patient were observed between both IC (difference
0.33 lesions, K value 0,76).Per-lesion discrepancy and impact concerning adverse
characteristic scoring is detailed in TableI. Disagreements 3 points per lesion analyzed
was observed in 21,1%. This discrepancy corresponded 61% of the global SS error.
Lesion
characteristics
Agreement
(%)
Kappa value
(IC 95%))
Discrepancy
score(points)
Global
Error (%)
Multivariate
analysis OR (IC
95%)
Segments
allocation
81,50% S/D 116 29,66751918 2,05 (1,48-2,83;
p0,001)
Segments
alloscation in
CTO
92,90% S/D 10 2,557544757 S/D
Heavy
calcificacion
73,20% 0,39 (0,26–0,52) 112 28,64450128 1,52 (0,61–3,82;
p0,35)
Bifurcations 92,00% 0,83 (0,75–0,91) 17 4,347826087 10,5 (2,18–50,6;
p0,003)
Medina
classification
85,70% 0,71 (0,53–0,88) 18 4,603580563 0,64 (0,14–2,84;
p0,56)
Angulation 
70‘
73,00% 0,45 (0,23–0,67) 28 7,16112532 0,98 (0,26–3,72;
p0,98)
Chronic total
occlution
98,60% 0,94 (0,87–1,00) 20 5,115089514 S/D
Blunt/Bridging 92,9%/
62,7%
S/D 16 4,092071611 S/D
Aorto-ostial 97,60% 0,85 (0,71–0,99) 5 1,278772379 4,11 (0,49
(34; p0,18)
Length (20
mm)
88,00% 0,61 (0,47 (0,74) 25 6,393861893 1,85 (0,59
(5,79; p0,28)
Severe
tortuosity
94,30% 0,42 (0,15 (0,69) 24 6,138107417 3,32 (0,80
(13,69; p0,09)
Thrombus 100,00% 1,00 (1,00 (1,00) 0 0 S/D
Conclusions: The interobserver correlation per lesion was good, except between severe
calcificacions. However, it did not generate systematic significant errors. Segments allocation
and bifurcations, generates significant errors that impact in global SS. Future image integration
and standard interpretation of complex lesion may help to reduce SS variability.
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Background: Early generation drug eluting stent (DES) overlap (OL) is associated with
impaired long-term clinical outcomes whereas the impact of OL with newer generation
DES is unknown. We sought to study the long-term clinical outcomes of patients with and
without OL of early and newer generation DES.
Methods: We analyzed the clinical outcomes of 3,133 patients included in a prospective,
registry of the unrestricted use of DES according to stent type (early generation sirolimus-
eluting stents [SES; N1,532] versus newer generation everolimus-eluting stents [EES;
N1,601]), and the presence or absence of OL and number of stents per vessel: 969 (30.9%)
patients with DES OL, 446 (14.2%) patients with multiple DES in a vessel without OL, and
1,718 (54.8%) patients with a single DES per vessel. The primary outcome was a composite
of death, myocardial infarction (MI), and target vessel revascularization (TVR).
Results: The primary endpoint was more common in patients with OL (25.1%) than in
patients with multiple DES without OL (20.8%, adj HR1.46, 95% CI 1.03-2.09) and
patients with a single DES (18.8%, adj HR1.74, 95% CI 1.34-2.25, p0.001) at 3 years,
driven largely by a higher risk of both MI and TVR. A stratified analysis by stent type
showed a higher risk of the primary outcome in SES treated patients with OL (28.7%)
compared to other SES groups (without OL: 22.6%, HR1.46, 95% CI 1.02-2.08; single
DES: 17.6%, HR1.73, 95% CI 1.34-2.23), but not between EES treated patients with
OL(22.3%) and other EES groups (without OL: 18.5%, HR1.24, 95% CI 0.83-1.85;
single DES: 20.4%, HR1.21, 95% CI 0.93-1.57).
Conclusions: DES OL is associated with impaired clinical outcomes during
long-term follow-up. Compared with early generation SES, newer generation EES
appear to overcome this limitation and provide similar clinical outcomes
irrespective of OL status.
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Cost Effectiveness of Everolimus-Eluting Stents Compared to Propensity
Score Matched Bare Metal Stents in Contemporary Clinical Practice
Robert Applegate1, Matthew Sacrinty1, Sanjay Gandhi1, Michael Kutcher1,
Renato Santos1, Timothy Smith1, William Little1
11Wake Forest School of Medicine, Winston-Salem, NC
Background: Everolimus-eluting stents (EES) reduce target lesion revascularization
(TLR) compared to bare metal stents (BMS), but cost more. Whether the increased costs
of EES are offset by reductions in costs of adverse clinical outcomes compared to BMS
is uncertain.
Methods: Percutaneous coronary intervention with EES (n1,024) and BMS (n819)
were performed at a single center (Wake Forest Baptist Medical Center) between January
2007 and December 2010. One year clinical outcomes and costs in 2010 dollars were
prospectively evaluated and compared for propensity score matched patients. Follow-up
was 94% for both groups.
Results: Baseline characteristics were similar for matched EES and BMS (n714 for both).
Clopidogrel use at 1 year was 87% EES vs. 61% BMS (p0.001). Initial cost difference
between DES and BMS was almost entirely offset by lower repeat revascularization costs at
1 year (5.6/100 patients), with clopidogrel costs representing 97% of the remaining cost
difference. Aggregate 1-year costs were $456 more ($508 less to $1,291 more) with EES
(p0.32), yielding an incremental cost effectiveness ratio of $8,135 per TLR avoided with
EES. The cost effectiveness profile of EES was highly sensitive to cost of clopidogrel.
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